Madrigal Pharmaceuticals, Inc.
NASDAQ: MDGL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Sibold
- Employees
- 528
- Headquarters
- West Conshohocken, United States
- IPO year
- 2007
- Market cap
- $11.7B
- Website
- https://www.madrigalpharma.com
Loading MDGL…
Loading profile data…Frequently asked questions about MDGL
What does Madrigal Pharmaceuticals, Inc. (MDGL) do?
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß ag...
Where does MDGL trade?
Madrigal Pharmaceuticals, Inc. (MDGL) trades on the NASDAQ Global Select.
What sector is MDGL in?
Madrigal Pharmaceuticals, Inc. (MDGL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Madrigal Pharmaceuticals, Inc.?
William J. Sibold is the chief executive officer of Madrigal Pharmaceuticals, Inc. (MDGL).
Where is Madrigal Pharmaceuticals, Inc. headquartered?
Madrigal Pharmaceuticals, Inc. is headquartered in United States.
Does MDGL pay a dividend?
Madrigal Pharmaceuticals, Inc. (MDGL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MDGL go public?
Madrigal Pharmaceuticals, Inc. (MDGL) completed its initial public offering in 2007.